All PlansCoverageHigh impact
Kebilidi® (Eladocagene Exuparvovec-Tneq)
UnitedHealthcare·Genetics, Oncology, Pediatrics·Medical Benefit Drug Policy
We identified it
Jul 2, 2026
Summary
Unable to extract actionable policy information from this document. The provided PDF content appears corrupted or improperly encoded, containing only binary/compressed data streams without readable policy text. The billing team cannot implement changes without access to the actual Kebilidi® policy details.
Action Required
URGENT: Request a readable copy of the Kebilidi® (Eladocagene Exuparvovec-Tneq) Medical Benefit Drug Policy from UHC. The current PDF file (medical-policy-update-bulletin-july-2026.pdf) is corrupted and unreadable. Do not process claims for this drug until the policy details can be reviewed. Contact UHC Provider Services to obtain a text-accessible version of this 4-week-old policy. Once obtained, review for prior authorization requirements, coverage criteria, billing codes (likely J-codes for gene therapy), and any documentation requirements. Flag this as a priority since this is a recent policy (4 weeks old) and gene therapies typically have high administrative requirements.